MARKET

PMN

PMN

Promis Neuroscie
NASDAQ
0.4401
-0.0300
-6.38%
After Hours: 0.4214 -0.0187 -4.25% 19:56 07/18 EDT
OPEN
0.4900
PREV CLOSE
0.4701
HIGH
0.4900
LOW
0.4384
VOLUME
415.69K
TURNOVER
--
52 WEEK HIGH
2.220
52 WEEK LOW
0.3800
MARKET CAP
14.39M
P/E (TTM)
-10.6304
1D
5D
1M
3M
1Y
5Y
1D
ProMIS Neurosciences Rises; HC Wainwright Starts Coverage With $4 Target
Dow Jones · 5d ago
Weekly Report: what happened at PMN last week (0707-0711)?
Weekly Report · 6d ago
HC Wainwright & Co. Initiates Coverage On ProMIS Neurosciences with Buy Rating, Announces Price Target of $4
Benzinga · 6d ago
Why ENDRA Life Sciences Shares Are Trading Higher By Over 61%; Here Are 20 Stocks Moving Premarket
Benzinga · 07/08 10:15
ProMIS Neurosciences Faces Nasdaq Compliance Challenge
TipRanks · 07/07 21:20
ProMIS Neurosciences Considers Reverse Stock Split to Meet Nasdaq Compliance
Reuters · 07/07 20:45
Weekly Report: what happened at PMN last week (0630-0704)?
Weekly Report · 07/07 11:29
Weekly Report: what happened at PMN last week (0623-0627)?
Weekly Report · 06/30 11:36
More
About PMN
ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

Webull offers Promis Neurosciences Inc stock information, including NASDAQ: PMN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PMN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PMN stock methods without spending real money on the virtual paper trading platform.